HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

Volume: 20, Issue: 5, Pages: 1115
Published: Mar 5, 2019
Abstract
Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-positive breast cancers. Currently,...
Paper Details
Title
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Published Date
Mar 5, 2019
Volume
20
Issue
5
Pages
1115
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.